LONDON (Reuters) - AstraZeneca is closing in on a site for its new $500 million home in Cambridge, with a biomedical park just south of the English city the most likely site, property industry sources said. Full story
LONDON (Reuters) - Standard & Poor's cut its credit outlook for AstraZeneca <AZN.L> to negative from stable on Monday in response to a major strategy update by the drugmaker's new chief executive last month. Full story
LONDON (Reuters) - AstraZeneca has suffered a fresh patent setback with a U.S. court decision that a patent protecting its Pulmicort Repsules asthma treatment is invalid, clearing the way for a generic copy from Actavis. Full story
CNBC's Seema Mody reports the latest from the Nasdaq: Drug makers Actavis and Astrazeneca reach an agreement to launch a Crestor generic in 2016.
LONDON (Reuters) - AstraZeneca is evaluating whether to enter the so-called biosimilars market, its new CEO Pascal Soriot said on Thursday. Full story
LONDON (Reuters) - AstraZeneca <AZN.L> is to cut around 1,600 jobs as it overhauls it research operations and consolidates drug development work in three major centers. Full story
The Chief Executive Officer of AstraZeneca, Pascal Soriot, is seen posing for a photograph in this undated picture provided by AstraZeneca in London on March 12, 2013. REUTERS/Marcus Lyon/AstraZeneca/Handout
Chief Executive Officer of AstraZeneca Pascal Soriot poses for a photograph in this undated picture provided by AstraZeneca in London on March 12, 2013. REUTERS/Marcus Lyon/AstraZeneca/Handout/Files
Chief Executive Officer of AstraZeneca, Pascal Soriot, poses for a photograph in this undated picture provided by AstraZeneca in London on March 12, 2013. REUTERS/Marcus Lyon/AstraZeneca/Handout/Files
